NEW YORK (GenomeWeb) – The Gene Editing Institute of the Helen F. Graham Cancer Center has signed an agreement to provide gene editing services and genetically modified cell lines to Analytical Biological Services (ABS), the partners announced today.

Under the terms of the three-year deal, the Gene Editing Institute will be the sole provider of gene editing services and genetically modified cell lines to ABS for replication, marketing, and distribution to pharmaceutical and biomedical research companies worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.